HP
CRSP icon

Harbourvest Partners’s CRISPR Therapeutics CRSP Stock Holding History

Harbourvest Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-97,770
Closed -$1.75M – 22
2017
Q3 		$1.75M Buy
+97,770
New +$1.77M 1.15% 10

Other funds holding CRSP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Harbourvest Partners's CRSP Position: Q4 2017 in Review

Harbourvest Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2017, closing a stake of 97,770 shares — an estimated $1.75M sold.

Harbourvest Partners first reported a position in CRSP in Q3 2017 and held it in 1 quarter. The position peaked at $1.75M in Q3 2017. 83 funds tracked by Wall St. Rank hold CRSP as of Q4 2017.

  • Harbourvest Partners reported no remaining CRISPR Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Harbourvest Partners sold 97,770 CRISPR Therapeutics shares in Q4 2017, an estimated $1.75M.
  • Harbourvest Partners first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 1 quarter.
  • Harbourvest Partners's CRISPR Therapeutics position peaked at $1.75M in Q3 2017.
  • 83 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2017.

Based on Harbourvest Partners's 13F filing for Q4 2017, filed 14 Feb 2018.